We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03012321
Recruitment Status : Unknown
Verified March 2021 by Maha Hussain, Northwestern University.
Recruitment status was:  Recruiting
First Posted : January 6, 2017
Last Update Posted : March 3, 2021
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Maha Hussain, Northwestern University

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : January 2022